Kakinada Institute Of Oncology Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 6.77 Cr
as on 16-11-2024
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.00 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit -208.23%
(FY 2023)
- Ebitda -209.98%
(FY 2023)
- Net Worth -347.36%
(FY 2023)
- Total Assets 228.01%
(FY 2023)
About Kakinada Institute Of Oncology
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 6.77 Cr.
The company currently has active open charges totaling ₹10.00 Cr.
Kaushik Hari, Mohan Tatapudi, Muralikrishna Mutyala, and Five other members serve as directors at the Company.
- CIN/LLPIN
U85100AP2021PTC118678
- Company No.
118678
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jun 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Guntur, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kakinada Institute Of Oncology?
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohan Tatapudi  | Director | 29-Jun-2021 | Current |
| Kaushik Hari | Director | 29-Jun-2021 | Current |
| Muralikrishna Mutyala | Director | Current | |
| Peketi Babu | Director | Current | |
| Chavala Devakanth | Director | Current | |
| Bala Abothu | Director | Current |
Financial Performance of Kakinada Institute Of Oncology.
Kakinada Institute Of Oncology Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 208.23% decrease in profit. The company's net worth observed a substantial decline by a decrease of 347.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kakinada Institute Of Oncology?
Unlock access to Kakinada Institute Of Oncology's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Sushruthahealth Care Services Private LimitedActive 5 years 4 months
Kaushik Hari is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 28 Mar 2022 | ₹10.00 Cr | Open |
How Many Employees Work at Kakinada Institute Of Oncology?
Unlock and access historical data on people associated with Kakinada Institute Of Oncology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kakinada Institute Of Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kakinada Institute Of Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
